A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib Phosphate Tablets in Chinese Adult Participants With Nonsegmental Vitiligo

This Phase 3 study will evaluate the efficacy and safety of oral povorcitinib phosphate compared with placebo in Chinese adults with nonsegmental vitiligo who are considered suitable for systemic therapy. Approximately 174 participants will be randomized 1:1 to povorcitinib phosphate 30 mg once daily or matching placebo for 52 weeks, followed by a 4-week safety follow-up. The primary efficacy assessment is proportion of participants achieving ≥75% improvement from baseline in face vitiligo area scoring index at Week 52.

开始日期2026-11-01

申办/合作机构-

NCT07588139

/ Completed临床1期

An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.

开始日期2026-05-18

申办/合作机构

Incyte Corp.

NCT07213973

/ Recruiting临床2期

A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

开始日期2026-02-02

申办/合作机构

Incyte Corp.

100 项与磷酸泊沃昔替尼相关的临床结果

登录后查看更多信息

100 项与磷酸泊沃昔替尼相关的转化医学

登录后查看更多信息

100 项与磷酸泊沃昔替尼相关的专利（医药）

登录后查看更多信息

项与磷酸泊沃昔替尼相关的文献（医药）

2026-10-01·ADVANCES IN THERAPY

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial

Article

作者: Passeron, Thierry ; Xue, Zhenyi ; Pandya, Amit G ; Ezzedine, Khaled ; Santos, Leandro L ; Erskine, Lois ; van Geel, Nanja ; Blauvelt, Andrew

INTRODUCTION:

A phase 2 trial (NCT04818346) of the oral Janus kinase 1 inhibitor povorcitinib demonstrated substantial total body and facial repigmentation over 52 weeks in adults with extensive nonsegmental vitiligo (NSV). Here, post hoc analyses evaluated povorcitinib efficacy in patients based on demographic and clinical characteristic subgroups, as well as affected body regions.

METHODS:

Data were pooled for 103 patients in the extension-evaluable population who received povorcitinib (15, 45, or 75 mg once daily) throughout the 52-week study. Efficacy among subgroups was evaluated using achievement of ≥ 50% reduction from baseline in total Vitiligo Area Scoring Index (T-VASI50) and ≥ 50%/≥ 75% reduction from baseline in facial VASI (F-VASI50/F-VASI75). Efficacy in the affected body regions was evaluated using VASI50 responses. Data were analyzed using descriptive statistics, and missing values were imputed as nonresponders.

RESULTS:

At Week 52, 34.0% (35/103) of patients achieved T-VASI50, 61.2% (63/103) achieved F-VASI50, and 45.6% (47/103) achieved F-VASI75. Repigmentation occurred across subgroups regardless of patient age, sex, race, Fitzpatrick skin type, affected body surface area, other autoimmune comorbidities, disease duration, or prior NSV treatment. In addition, VASI50 response rates increased consistently and, in most cases, without plateauing for each body region, ranging from 25.8% for the feet to 57.3% for the head and neck (excluding the face). Decreased rates of disease activity were also evident across body regions.

CONCLUSION:

In this exploratory post hoc analysis of adults with extensive NSV, oral povorcitinib produced clinically meaningful repigmentation (as measured by achievement of T-VASI50 and F-VASI75) across patient characteristic subgroups and body regions through 1 year of treatment. Response rates varied by body region, reinforcing the lengthy repigmentation process, especially in nonfacial areas, and highlighting the need to manage patient expectations and encourage adherence to long-term therapy.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT04818346.

2026-08-01·Dermatology and Therapy

Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of Povorcitinib

Article

作者: Xue, Zhenyi ; Santos, Leandro L ; Brant, Jason A ; Brown, Kurt ; DePietro, Michael

INTRODUCTION:

Patients with vitiligo reportedly have an increased risk of sensorineural hearing loss (SNHL), driven by the loss of extracutaneous melanocytes in the inner ear. In a phase 2 dose-ranging study, the oral, selective Janus kinase 1 inhibitor povorcitinib demonstrated substantial repigmentation in patients with extensive nonsegmental vitiligo through 52 weeks of treatment. This exploratory post hoc analysis of the phase 2 study evaluated the prevalence of hearing loss among enrolled patients and examined their associated demographic and clinical characteristics, as well as their audiometric response to povorcitinib.

METHODS:

SNHL was defined as a bone-conduction threshold of ≥ 25 dB in either ear and was assessed using all-frequencies average (AFA: 250, 500, 1000, 2000, 3000, 4000, 6000, 8000 Hz), pure-tone average (PTA: 500, 1000, 2000, 4000 Hz), and high-frequencies average (HFA: 2000, 3000, 4000, 6000, 8000 Hz).

RESULTS:

Of 162 patients assessed for hearing loss, SNHL prevalence at baseline was 10.5% (AFA), 11.7% (PTA), and 14.2% (HFA). Patients with versus without SNHL were significantly older and had significantly greater facial involvement. Following up to 52 weeks of povorcitinib treatment, bone-conduction hearing thresholds improved across all frequency ranges, although no definitive conclusions can be drawn. At week 52, mean percentage change from baseline in the left and right ears was as follows: AFA, - 18.7% (P = 0.08) and - 16.1% (P = 0.10); PTA, - 13.9% (P = 0.18) and - 7.2% (P = 0.25); and HFA, - 11.0% (P = 0.21) and - 12.6% (P = 0.18), respectively.

CONCLUSION:

SNHL was common in this patient population, suggesting that audiologic evaluation may be appropriate for some patients with vitiligo to support early detection and management of hearing loss. Changes in hearing with povorcitinib treatment require confirmation in larger patient populations. Graphical abstract available for this article.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT04818346.

2026-08-01·NATURE MEDICINE

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

Article

作者: Marzano, Angelo V ; Brown, Kurt ; Kelley, Jennifer ; Hayama, Koremasa ; Tian, Chenwei ; Reguiaï, Ziad ; Goldfarb, Noah ; van der Zee, Hessel H ; Kirby, Joslyn S ; Zouboulis, Christos C ; Santos, Leandro L ; Zhen, Huiling ; Sayed, Christopher J ; Martorell, Antonio ; Hsiao, Jennifer L ; Lev-Tov, Hadar ; Ehst, Benjamin D ; Frew, John W ; Bechara, Falk G ; Gooderham, Melinda J ; Porter, Martina L ; Del Marmol, Veronique ; Ackerman, Lindsay S

Abstract:

Although therapeutic options for hidradenitis suppurativa (HS) continue to expand, unmet needs remain substantial. We evaluated the efficacy and safety of povorcitinib (an oral, highly selective Janus kinase 1 (JAK1) inhibitor) in patients with moderate to severe HS in two randomized trials. STOP-HS1 and STOP-HS2 were identically designed, randomized, double-blind, placebo-controlled phase 3 trials. Adults with moderate to severe HS were randomized 2:2:1:1 to once-daily treatment through week 54: povorcitinib 45 mg; povorcitinib 75 mg; placebo with crossover at week 12 to povorcitinib 45 mg; or placebo with crossover at week 12 to povorcitinib 75 mg. The primary endpoint was HiSCR50 (≥50% decrease in total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count) at week 12. STOP-HS1/STOP-HS2 enrolled 608/619 patients, respectively. In both studies, both povorcitinib doses met the primary endpoint; in STOP-HS1, 82/204 (40%) patients in the povorcitinib 45-mg group and 82/202 (41%) in the 75-mg group versus 60/202 (30%) in the placebo group achieved HiSCR50 (OR (95% CI) 45 mg: 1.6 (1.1−2.5), P = 0.0240; 75 mg: 1.6 (1.1−2.4), P = 0.0214); corresponding values for STOP-HS2 were 88/208 (42%) and 88/208 (42%) versus 58/203 (29%; OR (95% CI) 45 mg: 1.8 (1.2−2.8), P = 0.0035; 75 mg: 1.9 (1.2−2.8); P = 0.0033). Through week 12, across STOP-HS1/STOP-HS2, serious treatment-emergent adverse events (AEs) occurred in 1−2% of patients across povorcitinib doses and in 2−3% with placebo; through week 54, serious AEs occurred in 5%/6% of patients receiving 45-mg/75-mg povorcitinib, respectively. The most frequent AEs among patients treated with 45-mg/75-mg povorcitinib were acne (17%/20%), nasopharyngitis (10%/12%) and upper respiratory tract infection (11%/10%). One death of undetermined etiology was reported and deemed unrelated to treatment. No new or unexpected safety findings were identified. Oral povorcitinib demonstrated significant improvements in HiSCR50 versus placebo and a favorable safety profile in patients with moderate to severe HS. ClinicalTrials.gov registration: NCT05620823 and NCT05620836 .

261

项与磷酸泊沃昔替尼相关的新闻（医药）

2026-10-22

·北京医学感染与传染研究

自然医学 32卷 7-10期

Nature Medicine Volume 32 Issue 7 自然医学 32卷 7期 https://www.nature.com/nm/volumes/32/issues/7 Editorial（社论） 1 Oncology must confront hidden side effects 肿瘤学必须正视隐匿不良反应 Nature Medicine volume 32（7）, page 2321 News（新闻） 2 Taming the inflamed heart 调控炎症性心脏病变 Charlotte Harrison Nature Medicine volume 32（7）, pages 2322-2323 News Feature（新闻专题） 3 When the real world becomes the trial 当现实世界成为临床试验场域 Marianne Guenot Nature Medicine volume 32（7）, pages 2324–2327 Correspondence（读者来信） 4 What Galen’s dissections reveal about tacit learning in modern medical education 盖伦解剖研究对现代医学教育中默会学习的启示 Andres PelavskiGabriele TorcolettiOrly Lewis Nature Medicine volume 32（7）, pages 2328–2329 5 What Utah’s clinical AI sandbox reveals about independent oversight 犹他州临床人工智能沙箱对独立监管机制的启示 Rahul GorijavoluNikhil JaiswalLeo Anthony Celi Nature Medicine volume 32（7）, pages 2330–2332 6 A case of artificial intelligence-enhanced diagnostics leading to heart transplantation 人工智能辅助诊断促成心脏移植一例 Heidi S. HartmanJoshua FinerPierre Elias Nature Medicine volume 32（7）, pages 2333–2334 7 Unintended consequences of legacy oversight in digital medicine 数字医学领域传统监管模式带来的非预期后果 Jochen K. LennerzDaniela AllendeAnne M. Stowman Nature Medicine volume 32（7）, pages 2335–2337 8 Incretin therapies, nutrition and food insecurity in the UK 英国肠促胰素治疗、营养状况与粮食不安全问题 Marie SpreckleyCara F. RuggieroAdrian Brown Nature Medicine volume 32（7）, pages 2338–2339 World View（全球观点） 9 Manageable toxicity is not a label — it is an oxymoron 可控制毒性并非标签，而是矛盾表述 From the patient’s perspective, toxicity is manageable only when it is met with empathy. 从患者视角而言，只有饱含人文关怀，不良反应才谈得上可控。 Laura Book Nature Medicine volume 32（7）, page 2340 10 Downplaying toxicities in cancer drug trials is not acceptable 肿瘤药物临床试验中淡化不良反应不可取 Bishal Gyawali Nature Medicine volume 32（7）, page 2341 Comment（述评） 11 Wearables as personal health custodians 可穿戴设备：个人健康守护者 Lei LuJosip Car Nature Medicine volume 32（7）, pages 2342–2345 12 Australia legislates against genetic discrimination in life insurance 澳大利亚立法禁止人寿保险领域的基因歧视 Jane Tiller Nature Medicine volume 32（7）, pages 2346–2348 13 A roadmap to competitive preclinical packages 具备竞争力的临床前研究方案构建路线图 Mustafa KhasrawMegan C. BenzJose R. Conejo-Garcia Nature Medicine volume 32（7）, pages 2349–2352 14 Brain Health for Economic Resilience: a data-driven framework for the brain-positive economic transition 保障大脑健康助力经济韧性：推动益脑经济转型的数据驱动框架 Harris A. EyreRym AyadiSimon Fischer-Baum Nature Medicine volume 32（7）, pages 2353–2355 News & Views（新闻与观点） 15 Long-term health risks of e-cigarettes after smoking cessation 戒烟后使用电子烟的长期健康风险 Mahdi SheikhPamela M. Ling Nature Medicine volume 32（7）, pages 2356–2357 16 CAR T cells take on precancers CAR-T细胞靶向癌前病变 Eric M. JurgensSham Mailankody Nature Medicine volume 32（7）, pages 2358–2359 17 Lassa fever countermeasures gather pace 拉沙热防控举措加速推进 Daniel Jenkin Nature Medicine volume 32（7）, pages 2360–2361 18 Shifting the goalposts in obesity drug development 肥胖药物研发目标的重新界定 W. Timothy Garvey Nature Medicine volume 32（7）, pages pages 2362–2363 Research Briefings（研究简报） 19 General-purpose chatbots outperform clinical AI tools on physicians’ real-world questions 通用对话机器人在医师现实临床问题上表现优于专用临床人工智能工具 Nature Medicine volume 32（7）, pages 2364–2365 20 An AI framework for multi-disease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Nature Medicine volume 32（7）, pages 2366–2367 Perspectives（前瞻观点） 21 Immune aging biomarkers for clinical trials 适用于临床试验的免疫衰老生物标志物 Andrea CiprianoJamie JusticeChiara M. S. Herzog Nature Medicine volume 32（7）, pages 2368–2382 Review Articles（综述） 22 Biological aging clocks in health and disease 健康与疾病状态下的生物学衰老时钟 Tony Wyss-CorayEric J. Topol Nature Medicine volume 32（7）, pages 2383–2394 Matters Arising（学术争鸣） 23 Limited evidence of AI superiority in seasonal influenza vaccine strain selection 尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势 Simon P. J. de JongColin A. Russell Nature Medicine volume 32（7）, pages 2395–2397 24 Reply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selection 对《尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势》一文的回应 Wenxian ShiJeremy WohlwendRegina Barzilay Nature Medicine volume 32（7）, pages 2398–2400 Brief Communications（简讯） 25 Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba 2024年古巴奥罗普切热暴发的时空传播特征 Rosario GravierMelissa M. PerezMaria G. Guzman Nature Medicine volume 32（7）, pages 2401–2404 26 General-purpose large language models outperform specialized clinical AI tools on medical benchmarks 通用大语言模型在医学基准测试中优于专用临床人工智能工具 Krithik VishwanathAnton AlyakinEric Karl Oermann Nature Medicine volume 32（7）, pages 2405–2409 Articles（论著） 27 Electronic cigarette use after smoking cessation and lung cancer risk 戒烟后使用电子烟与肺癌风险 Yeon Wook KimEung Joo ParkChoon-Taek Lee Nature Medicine volume 32（7）, pages 2410–2419 28 Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial Ciltacabtagene autoleucel治疗高危冒烟型（无症状）多发性骨髓瘤：CAR-PRISMⅡ期临床试验 Omar NadeemDavid M. Cordas dos SantosIrene M. Ghobrial Nature Medicine volume 32（7）, pages 2420–2429 29 Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial Cibisatamab联合FAP-4-1BBL治疗微卫星稳定型结直肠癌：Ⅰb期临床试验 Ignacio MeleroTamara TanosVictor Moreno Nature Medicine volume 32（7）, pages 2430–2439 30 Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, pages 2440–2448 31 Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial 抗LAG-3单抗联合或不联合抗PD-1单抗治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Michael LimXiaobu YeStuart A. Grossman Nature Medicine volume 32（7）, pages 2449–2460 32 Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial 立体定向体部放疗联合度伐利尤单抗与奥来鲁单抗新辅助治疗ER阳性HER2阴性乳腺癌：随机Ⅱ期临床试验 Alex De CaluwéIsabelle DesmoulinsLaurence Buisseret Nature Medicine volume 32（7）, pages 2461–2472 33 Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial ctDNA阳性结直肠癌术后辅助化疗：随机Ⅲ期临床试验 Hideaki BandoJun WatanabeTakeshi Kato Nature Medicine volume 32（7）, pages 2473–2480 34 Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie GomezRachel A. DiCioccioEugene I. Hwang Nature Medicine volume 32（7）, pages 2481–2493 35 AI framework for multidisease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Xiayin ZhangQinyi LiHonghua Yu Nature Medicine volume 32（7）, pages 2494–2503 36 Long-term independent use of an intracortical brain–computer interface for speech and cursor control 皮层内脑机接口用于语音与光标控制的长期独立应用研究 Nicholas S. CardTyler Singer-ClarkDavid M. Brandman Nature Medicine volume 32（7）, pages 2504–2510 37 Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial 含佐剂灭活狂犬病毒载体拉沙病毒疫苗在健康成人中的Ⅰ期临床试验 Justin R. OrtizDrishya KurupMatthias J. Schnell Nature Medicine volume 32（7）, pages 2511–2521 38 Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial 法匹拉韦治疗拉沙热：开放标签随机对照Ⅱ期临床试验 Cyril EramehKevin OkwaraekeMirjam Groger Nature Medicine volume 32（7）, pages 2522–2532 39 Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial 双特异性广谱中和抗体10E8.4/iMab在HIV-1感染者与健康人群中的部分随机Ⅰ期临床试验 Deborah A. TheodoreBryan T. MayerMagdalena E. Sobieszczyk Nature Medicine volume 32（7）, pages 2533–2545 40 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial 15菌株活体生物制剂与同源供体粪菌移植治疗复发性艰难梭菌感染：随机Ⅰb期临床试验 Lukas BethlehemLorenza BartuAri Grinspan Nature Medicine volume 32（7）, pages 2546–2555 41 Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection 固有免疫应答水平可预测人工流感感染后细胞免疫增强与临床发病情况 Loukas PapargyrisJiayun XuChristopher Chiu Nature Medicine volume 32（7）, pages 2556–2569 42 Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial 多巴胺激动剂普拉克索治疗快感缺失型抑郁症的疗效与靶点作用验证：随机安慰剂对照试验 Filip VentorpMarie AspDaniel Lindqvist Nature Medicine volume 32（7）, pages 2570–2578 43 Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial 脊髓电刺激改善慢性卒中后偏瘫患者上肢运动功能：可行性临床试验 Roberto M. de FreitasShovan BhatiaMarco Capogrosso Nature Medicine volume 32（7）, pages 2579–2590 44 A neuroprosthesis for restoring hand movement and sensation in a person with complete tetraplegia 神经假体用于重建完全四肢瘫痪患者手部运动与感觉功能 Santosh ChandrasekaranSarah K. WandeltChad E. Bouton Nature Medicine volume 32（7）, pages pages2591–2601 45 Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial 双靶点基因疗法治疗帕金森病：多中心Ⅰ期临床试验 Mengyue NiuJifeng GuoJun Liu Nature Medicine volume 32（7）, pages 2602–2609 46 Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial 阿巴西普对比羟氯喹预防复发性风湿症进展为类风湿关节炎：随机开放标签试验 Raimon SanmartiCarolina Pérez-GarcíaIsabel Haro Nature Medicine volume 32（7）, pages 2610–2618 47 Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial 寡核苷酸-siRNA偶联药物治疗SOD1相关肌萎缩侧索硬化：Ⅰ期临床试验 Weiqi ChenLingling JiangYilong Wang Nature Medicine volume 32（7）, pages 2619–2628 48 Multinational validation of the PREVENT and SCORE2心血管风险方程 across 6.4 million individuals 基于640万人群的多国验证：PREVENT与SCORE2心血管风险预测方程 Brendon L. NeuenRupert W. MajorVilmantas Giedraitis Nature Medicine volume 32（7）, pages 2629–2638 49 Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial Cliramitug清除心脏转甲状腺素蛋白淀粉样物质：NI006-101试验长期随访结果 Peter C. KahrFabian aus dem SiepenPeter van der Meer Nature Medicine volume 32（7）, pages 2639–2646 50 Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial 小剂量地高辛治疗射血分数降低或轻度降低心力衰竭：随机对照试验 D. J. van VeldhuisenM. RienstraP. van der Meer Nature Medicine volume 32（7）, pages 2647–2653 51 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 微小RNA抑制剂CDR132L治疗心肌梗死后左室射血分数降低患者：随机Ⅱ期临床试验 Johann BauersachsScott D. SolomonThomas Thum Nature Medicine volume 32（7）, pages 2654–2661 52 Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial 司美格鲁肽对比安慰剂治疗减重手术术后减重不佳人群：双盲随机安慰剂对照试验 Chloe StanleyRitwika MallikJanine Makaronidis Nature Medicine volume 32（7）, pages 2662–2672 53 Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Apitegromab用于替尔泊肽减重过程中维持瘦体重：随机双盲安慰剂对照Ⅱ期临床试验 Richard E. PratleyDouglas Scott DenhamJing L. Marantz Nature Medicine volume 32（7）, pages 2673–2678 54 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Orforglipron用于维持减重效果：双盲随机Ⅲb期ATTAIN-MAINTAIN试验 Louis J. AronneDeborah B. HornNeena Xavier Nature Medicine volume 32（7）, pages 2679–2687 Amendments & Corrections（勘误与更正） 55 Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 作者更正：基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, page 2688 56 Author Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial 作者更正：数字虚拟化身疗法治疗精神病幻听症状：Ⅱ/Ⅲ期AVATAR2临床试验 Philippa A. GaretyClementine J. EdwardsThomas Ward Nature Medicine volume 32（7）, page 2689 57 Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study 作者更正：1990–2023年204个国家苯丙胺、大麻、可卡因与阿片类物质使用的全球疾病负担研究 Jiseung KangHyeon Jin KimDong Keon Yon Nature Medicine volume 32（7）, page 2690 58 Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial 撤稿声明：时辰免疫化疗治疗非小细胞肺癌：随机Ⅲ期临床试验 Zhe HuangLiang ZengYongchang Zhang Nature Medicine volume 32（7）, page 2691 Nature Medicine Volume 32 Issue 8 自然医学 32卷 8期 https://www.nature.com/nm/volumes/32/issues/8 Editorial（社论） 1 Anti‑aging interventions need less hype and more clinical evidence 抗衰老干预：少一些炒作，多一些临床证据 Editorial Nature Medicine volume 32（8）, page 2693 News（新闻） 2 A turning point for gene editing in severe blood disorders 基因编辑治疗重症血液疾病迎来转折点 Carrie Arnold Nature Medicine volume 32（8）, pages 2694-2696 News Feature（新闻特写） 3 Sleep as therapy 睡眠疗法 Carrie Arnold Nature Medicine volume 32（8）, pages 2697–2700 Correspondence（通信） 4 Genetic–exposome interactions and aging clocks in dementia: the ReDLat2 initiative 遗传‑暴露组相互作用与痴呆衰老时钟：ReDLat2研究计划 Agustin IbáñezJennifer S. YokoyamaBruce L. Miller Nature Medicine volume 32（8）, pages 2701–2703 5 Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures 无疫苗与治疗药物情况下的本迪布焦埃博拉疫情：公共卫生基础措施比边境封锁更为重要 Ngashi NgongoMosoka Papa FallahJean Kaseya Nature Medicine volume 32（8）, pages 2704–2705 6 Fertilizer scarcity as a failure of global health governance 肥料短缺：全球卫生治理的一项失败 Alaha NasariAmina NasariJessica Fanzo Nature Medicine volume 32（8）, pages 2706–2707 7 Mapping the human chemical exposome for public health 面向公共卫生的人类化学暴露组图谱绘制 Arthur DavidSarah LennonMichel Samson Nature Medicine volume 32（8）, pages 2708–2710 World View（全球视野） 8 When caution becomes harm 当谨慎变为伤害 Simone N. Vigod Nature Medicine volume 32（8）, page 2711 Comment（述评） 9 Enabling secure discovery in trusted research environments with improved tooling 依托优化工具在可信研究环境中实现安全数据挖掘 Vincent J. StraubMelinda C. Mills Nature Medicine volume 32（8）, pages 2712–2715 10 Reinventing biotech systems for patient impact 重塑生物技术体系，惠及患者 Kushal T. KadakiaYashodhara DashAnaeze C. Offodile II Nature Medicine volume 32（8）, pages 2716–2719 11 Why large‑scale randomized trials of live‑attenuated shingles vaccination for dementia prevention are urgently needed 亟需开展减毒活带状疱疹疫苗预防痴呆的大规模随机对照试验 Pascal Geldsetzer Nature Medicine volume 32（8）, pages 2720–2723 12 Inspiring, shaping and sustaining an African research & development agenda 推动、构建并维系非洲研发议程 Mosoka P. FallahMisaki WayengeraJean Kaseya Nature Medicine volume 32（8）, pages 2724–2726 13 Data rights are the missing pillar for modernizing consent in medicine 数据权利：医学知情同意现代化的缺失支柱 Nada S. Salem Nature Medicine volume 32（8）, pages 2727–2728 Q&A（问答） 14 Reinventing health communication for the digital era 数字时代下重塑健康传播 Natalie Healey Collection: Nature Medicine Commission on Quality Health Information for All Nature Medicine volume 32（8）, pages 2729–2731 News & Views（新闻与观点） 15 Adaptive brain stimulation 2.0 for Parkinsonian gait 用于帕金森病步态障碍的第二代自适应脑刺激 Arjun BalachandarAlfonso Fasano Nature Medicine volume 32（8）, pages 2732–2734 16 A second chance for gene therapy to restore natural hearing 基因治疗重获契机，助力恢复天然听力 Nicola Strenzke Nature Medicine volume 32（8）, pages 2735–2737 17 From RAS inhibitor resistance to rational combination strategies 从RAS抑制剂耐药到合理联合治疗策略 Paula LynchTeresa MacarullaGrainne M. O’Kane Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2738–2740 18 Deciphering the role of histidine in cancer 解析组氨酸在肿瘤中的作用 Feyza CansizAmanda N. PopeAlpaslan Tasdogan Nature Medicine volume 32（8）, pages 2741–2742 Research Briefings（研究简报） 19 Learning from routine health system data builds better neuroimaging AI models 基于常规卫生系统数据训练构建更优神经影像人工智能模型 Research Briefing Nature Medicine volume 32（8）, pages 2743–2744 20 Early detection of Alzheimer’s disease with circular RNA from blood 基于血液环状RNA实现阿尔茨海默病早期检测 Nature Medicine volume 32（8）, pages 2745–2746 21 Non‑invasive tests for the evaluation of liver fibrosis in MASLD 代谢相关脂肪性肝病肝纤维化的无创评估检测 Nature Medicine volume 32（8）, pages 2747–2748 22 Multi‑omics maps human–pig interactions in extracorporeal liver cross‑circulation 多组学解析体外肝交叉循环中人‑猪相互作用 Nature Medicine volume 32（8）, pages 2749–2750 23 Biological aging might help to explain the rising risk of early‑onset cancer 生物衰老或可解释早发性肿瘤风险升高现象 Nature Medicine volume 32（8）, pages 2751–2752 24 Delivering the benefits of genomic data reanalysis for diagnosis equitably and at scale 公平、规模化发挥基因组数据再分析的诊断价值 Nature Medicine volume 32（8）, pages 2753–2754 25 Why high scores do not mean application readiness for health AI 为何高分不等于健康人工智能具备实际应用就绪度 Nature Medicine volume 32（8）, pages 2755–2756 Perspectives（观点） 26 Type 2 diabetes prevention across the life course 全生命周期的2型糖尿病预防 Yiying WangJennifer L. SargentAndreas L. Birkenfeld Nature Medicine volume 32（8）, pages 2757–2773 27 The next generation of antibody–drug conjugates 新一代抗体‑药物偶联物 F. MoseleA. PeltierF. André Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2774–2785 Brief Communications（简讯） 28 Clinical profile and genomic characterization of the 2026 Bundibugyo virus index case in Uganda 乌干达2026年本迪布焦病毒首发病例的临床特征与基因组分析 Andrew NsawotebbaIsaac SsewanyanaDiana Atwine Nature Medicine volume 32（8）, pages 2786–2789 Articles（论著） 29 Immersive virtual reality with synchronous neurostimulation for upper‑limb recovery after stroke: a randomized feasibility trial 沉浸式虚拟现实联合同步神经刺激用于脑卒中后上肢功能恢复：一项随机可行性试验 Giuseppe Valerio AurucciOlivera DjordjevicStanisa Raspopovic Nature Medicine volume 32（8）, pages 2790–2802 30 Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial 自适应深部脑刺激用于帕金森病动态步态调控：一项随机可行性试验 Kenneth H. LouieJannine P. BalakidDoris D. Wang Nature Medicine volume 32（8）, pages 2803–2814 31 Activity‑dependent adaptive deep brain stimulation improves gait in Parkinson’s disease 活动依赖性自适应深部脑刺激改善帕金森病患者步态 Stefano ScafaValeria de SetaEduardo M. Moraud Nature Medicine volume 32（8）, pages 2815–2830 32 Health system learning enables generalist neuroimaging models 基于卫生系统数据学习构建通用型神经影像模型 Akhil KondepudiAkshay RaoTodd Hollon Nature Medicine volume 32（8）, pages 2831–2837 33 Individualized antisense oligonucleotides for SCN2A‑related developmental epileptic encephalopathy 针对SCN2A相关发育性癫痫性脑病的个体化反义寡核苷酸治疗 Olivia Kim‑McManusLaurence MignonElizabeth Berry‑Kravis Nature Medicine volume 32（8）, pages 2838–2845 34 Re‑administration of AAV‑mediated gene therapy for OTOF‑related deafness: a single‑arm trial OTOF相关耳聋腺相关病毒介导基因治疗的再次给药：一项单臂临床试验 Xintai FanLonglong ZhangYilai Shu Nature Medicine volume 32（8）, pages 2846–2856 35 Blood‑based circular RNAs for early diagnosis of Alzheimer’s disease 基于血液环状RNA的阿尔茨海默病早期诊断 Bridget PhillipsJessie SanfordCarlos Cruchaga Nature Medicine volume 32（8）, pages 2857–2864 36 Acquired resistance to the RAS(ON) multi‑selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer RAS(ON)高选择性抑制剂daraxonrasib获得性耐药指导胰腺癌合理联合治疗策略 Ida AronchikSumit KarMallika Singh Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2865–2877 37 MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, pages 2878–2887 38 Savolitinib in MET‑amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 赛沃替尼治疗MET扩增胃癌或胃食管结合部腺癌：Ⅱ期临床试验 Zhi PengTianshu LiuZhongxian Zheng Nature Medicine volume 32（8）, pages 2888–2897 39 SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, pages 2898–2908 40 FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial FcRH5×CD3双特异性抗体ce vostamab治疗复发难治多发性骨髓瘤：Ⅰ期临床试验 Adam D. CohenJoshua RichterAmrita Krishnan Nature Medicine volume 32（8）, pages 2909–2917 41 Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling 基于血浆谱分析筛选肿瘤免疫治疗疗效的代谢决定因素 Déborah SuissaMarine FidelleLaurence Zitvogel Nature Medicine volume 32（8）, pages 2918–2932 42 Polypill for heart failure with reduced ejection fraction: the POLY‑HF randomized trial 射血分数降低心力衰竭复方制剂：POLY‑HF随机临床试验 Ambarish PandeyNeil KeshvaniThomas J. Wang Nature Medicine volume 32（8）, pages 2933–2940 43 Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, pages 2941–2947 44 Survodutide in adults with obesity and metabolic dysfunction‑associated steatotic liver disease: SYNCHRONIZE‑MASLD, a randomized, double‑blind, placebo‑controlled phase 3 trial Survodutide治疗合并代谢相关脂肪性肝病的肥胖成人：SYNCHRONIZE‑MASLD随机双盲安慰剂对照Ⅲ期临床试验 Lee M. KaplanElena StartsevaPaul Hellstern Nature Medicine volume 32（8）, pages 2948–2958 45 Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study 代谢相关脂肪性肝炎及肝纤维化影像与血清诊断生物标志物的前瞻性验证：LITMUS影像研究 Michael PavlidesYasaman ValiQuentin M. Anstee Nature Medicine volume 32（8）, pages 2959–2969 46 Longitudinal multiomics profiling of extracorporeal cross‑circulation with pig liver xenografts in human decedents 人逝者猪肝异种移植体外交叉循环的纵向多组学分析 Qian GuoChan WangBrendan J. Keating Nature Medicine volume 32（8）, pages 2970–2982 47 Biological aging and generational shifts in early‑onset cancer risk 生物衰老与早发性肿瘤风险的代际变迁 Ruiyi TianXiaoyu ZongYin Cao Nature Medicine volume 32（8）, pages 2983–2990 48 Automated reanalysis of genomic data for rare disease diagnostics at scale 面向大规模罕见病诊断的基因组数据自动化再分析 Matthew J. WellandK. D. AhlquistZornitza Stark Nature Medicine volume 32（8）, pages 2991–2999 49 Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people 可解释人工智能皮肤病诊断对临床医师与普通人群的差异化影响 Xuhai ‘Orson’ XuHaoyu HuMarzyeh Ghassemi Nature Medicine volume 32（8）, pages 3000–3009 50 Generalizable AI predicts immunotherapy outcomes across cancers and treatments 泛化人工智能跨肿瘤类型与治疗方案预测免疫治疗疗效 Wanxiang ShenIntae MoonMarinka Zitnik Nature Medicine volume 32（8）, pages 3010–3022 51 Evaluating the robustness and readiness of large frontier models in health AI applications 健康人工智能应用中大前沿模型的稳健性与就绪度评估 Yu GuJingjing FuPaul Vozila Nature Medicine volume 32（8）, pages 3023–3031 52 Generative AI‑enabled clinical decision support system in primary care: a pragmatic, cluster‑randomized trial 基层医疗机构生成式人工智能临床决策支持系统：一项实用整群随机试验 Ambrose AgweyuPaul MwanikiBilal A. Mateen Nature Medicine volume 32（8）, pages 3032–3039 53 Integrated care pathway in individuals with Long COVID: STIMULATE‑ICP, a cluster‑randomized, phase 3 trial 长新冠患者综合护理路径：STIMULATE‑ICP整群随机Ⅲ期临床试验 Amitava BanerjeeGordon PrescottYi Mu Nature Medicine volume 32（8）, pages 3040–3047 54 Maternal 6‑valent group B Streptococcus vaccine in non‑pregnant and pregnant females: a randomized phase 1/2 trial B族链球菌六价母体疫苗在非妊娠及妊娠女性中的随机Ⅰ/Ⅱ期临床试验 Shabir A. MadhiHasra SnaggsAlejandra Gurtman Nature Medicine volume 32（8）, pages 3048–3059 55 The genetic architecture of fibromyalgia across 2.5 million individuals 基于250万人群的纤维肌痛遗传结构研究 Isabel KerrebijnGyda BjornsdottirMichael Wainberg Nature Medicine volume 32（8）, pages 3060–3070 56 Povorcitinib for hidradenitis suppurativa: the randomized, double‑blind, placebo‑controlled STOP‑HS1 and STOP‑HS2 phase 3 trials Povorcitinib治疗化脓性汗腺炎：随机双盲安慰剂对照STOP‑HS1、STOP‑HS2两项Ⅲ期临床试验 Martina L. PorterAntonio MartorellChristos C. Zouboulis Nature Medicine volume 32（8）, pages 3071–3081 Analysis（分析） 57 A meta‑analysis of the long‑term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials 纳入51项随机试验的降压治疗对主要心血管病风险长期影响的荟萃分析 Qianqian YangZeinab BidelKazem Rahimi Nature Medicine volume 32（8）, pages 3082–3092 Amendments & Corrections（修订与勘误） 58 Author Correction: SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 作者勘误：靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, page 3093 59 Author Correction: MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 作者勘误：靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, page 3094 60 Publisher Correction: Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 出版方勘误：口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, page 3095 Nature Medicine Volume 32 Issue 9 自然医学 32卷 9期 https://www.nature.com/nm/volumes/32/issues/9 Editorial（社论） 1 To bridge the evidence gap in women’s health, look at the real world 弥合女性健康领域证据缺口：着眼真实世界 Nature Medicine volume 32（9）, page3097 News（新闻） 2 AI decision support is scaling-up fast — can the evidence keep up? AI决策支持系统快速普及——证据能否跟上发展？ Paul Webster Nature Medicine volume 32（9）, pages 3098–3099 News Feature（新闻特写） 3 Can traditional medicines go mainstream? 传统药物能否走向主流？ Ben Deighton Nature Medicine volume 32（9）, pagespages 3100–3103 Correspondence（通信） 4 Global access to different classes of diabetes medicines: a framework for targeted policy actions 不同类别糖尿病药物的全球可及性：一项针对性政策行动框架 Felix Teufel, Nomathemba Chandiwana, Till Bärnighausen Nature Medicine volume 32（9）, pages 3104–3106 5 A new additive in the opioid supply is causing disastrous complications 阿片类药物供应链中的新型添加物引发严重并发症 Cara Borelli Nature Medicine volume 32（9）, page 3107 6 Reconstructing disease burden data in armed conflict 武装冲突地区疾病负担数据的重建 Hussein ALMasri, Zining Luo, Huda Lahham Nature Medicine volume 32（9）, pages 3108–3109 7 Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty 监管碎片化：区域疫苗自主的隐性障碍 Mnotho Ngcobo Nature Medicine volume 32（9）, pages 3110–3111 8 Food is medicine: an opportunity to transform nutrition care in oncology 食物即药物：肿瘤营养诊疗变革的机遇 Fang Fang Zhang Nature Medicine volume 32（9）, pages 3112–3113 World View（全球观点） 9 Obesity medicines as disruptive innovation 作为颠覆性创新的肥胖治疗药物 Naveed Sattar Nature Medicine volume 32（9）, page 3114 Comment（述评） 10 Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria 2024版McDonald诊断标准出台后多发性硬化面临的挑战与未来方向 Jiwon Oh, Frederik Barkhof, Peter A. Calabresi Nature Medicine volume 32（9）, pages 3115–3119 11 Studying vanishing dietary diversity before it is lost: the World Diet Initiative 在饮食多样性消失前开展研究：世界饮食计划 Quirijn de Mast, Carly V. Brown, Mihai G. Netea Nature Medicine volume 32（9）, pages 3120–3123 12 Governing the social production of care: the hidden foundation of health systems 照护的社会供给治理：卫生体系的隐性基石 Jo-An Occhipinti, Ante Prodan, J. Jaime Miranda Nature Medicine volume 32（9）, pages 3124–3127 13 Toward a test of medical AI superintelligence 迈向医学人工智能超级智能的检验 Ethan Goh, David Wu, Jonathan H. Chen Nature Medicine volume 32（9）, pages 3128–3130 14 Rethinking the global health system for a new international order 面向国际新秩序重新思考全球卫生体系 Kumanan Rasanathan, Keith Cloete, John-Arne Røttingen Nature Medicine volume 32（9）, pages 3131–3135 News & Views（新闻与观点） 15 A multimodal murmuration for immunotherapy 免疫治疗的多模态协同效应 Raquel Perez-Lopez, Mireia Crispin-Ortuzar Nature Medicine volume 32（9）, pages 3136–3137 16 Beyond the breakthrough for RAS-driven cancers RAS驱动肿瘤：突破之外的探索 Rich C. King, Erica S. Tsang, Jennifer J. Knox Nature Medicine volume 32（9）, pages 3138–3139 17 Waking from the nightmare of PTSD 从创伤后应激障碍的梦魇中苏醒 Murray B. Stein Nature Medicine volume 32（9）, pages 3140–3141 18 The trials of translating psilocybin treatment from research to practice 裸盖菇素治疗从研究走向临床应用的挑战 Liliana Galindo, Anya Ragnhildstveit, Benjamin J. G. Illingworth Nature Medicine volume 32（9）, pages 3142–3143 19 Putting epigenetic aging clocks on trial 表观遗传衰老时钟的临床验证 Steve Horvath Nature Medicine volume 32（9）, pages 3144–3145 Research Briefings（研究简报） 20 County surveillance failed to detect that measles transmission reached epidemic threshold in schools 县级监测未能发现麻疹在学校传播已达流行阈值 Nature Medicine volume 32（9）, pages 3146–3147 21 The px1 locus is linked to declining susceptibility to malaria drugs in Uganda 乌干达px1基因座与抗疟药物敏感性下降相关 Nature Medicine volume 32（9）, pages 3148–3149 22 Isthmin 2 could determine the early origins of preeclampsia and fetal growth restriction Isthmin 2可提示子痫前期与胎儿生长受限的早期起源 Nature Medicine volume 32（9）, pages 3150–3151 23 Scaling rapid whole-genome sequencing for critical pediatric care in the Middle East 中东地区危重患儿快速全基因组测序的规模化应用 Nature Medicine volume 32（9）, pages 3152–3153 Perspectives（观点） 24 How to build an AI-driven digital organism 如何构建人工智能驱动的数字有机体 Le Song, Eran Segal, Eric Xing Nature Medicine volume 32（9）, pages 3154–3163 Review Articles（综述） 25 Induced pluripotent stem cells from discovery to translation 诱导多能干细胞：从发现到临床转化 Jaecheol Lee, Todd Herron, Joseph C. Wu Nature Medicine volume 32（9）, pages 3164–3180 Articles（论著） 26 County, district and community-level measles transmission in the United States in 2013−2025 2013–2025年美国县、辖区及社区层面的麻疹传播 Siyu Chen, Ana I. Bento Nature Medicine volume 32（9）, pages 3181–3191 27 Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda 乌干达恶性疟原虫PX1多态性（与抗疟药敏感性下降相关）的出现与传播 Karamoko Niaré, Bersabeh Tafesse, Melissa D. Conrad Nature Medicine volume 32（9）, pages 3192–3202 28 End-to-end multimodal pathology foundation model with clinical dialogue 具备临床对话能力的端到端多模态病理基础大模型 Eugene Vorontsov, George Shaikovski, Siqi Liu Nature Medicine volume 32（9）, pages 3203–3213 29 AI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trial 基于AI的遗传性视网膜疾病临床决策支持系统：一项多中心随机试验 Huixun Jia, Bo Qian, Xiaodong Sun Nature Medicine volume 32（9）, pages 3214–3223 30 Clinical decision support in hematological malignancies using a case-grounded AI agent 基于案例AI智能体用于血液恶性肿瘤的临床决策支持 Julian Zoller, Michael Kalz, Mirco J. Friedrich Nature Medicine volume 32（9）, pages 3224–3234 31 Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC 可解释AI决策支持工具在非小细胞肺癌中的临床可用性及多模态模型评估 Arsela Prelaj, Vanja Miskovic, Giovanni Scoazec Nature Medicine volume 32（9）, pages 3235–3247 32 An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial 携带Gq/11抑制剂载荷的抗PMEL抗体药物偶联物治疗GNAQ/GNA11突变黑色素瘤：Ⅰ期临床试验 Matteo S. Carlino, Ellen Kapiteijn, Emiliano Calvo Nature Medicine volume 32（9）, pages 3248–3258 33 Englumafusp alfa plus glofitamab in Bcell non-Hodgkin lymphoma: a phase 1 trial Englumafusp alfa联合格罗非单抗治疗B细胞非霍奇金淋巴瘤：Ⅰ期临床试验 Martin Hutchings, Michael Dickinson, Franck Morschhauser Nature Medicine volume 32（9）, pages 3259–3267 34 Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial 颅内输注靶向B7-H3的CAR-T细胞治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Yang Zhang, Xiaohan Chi, Gangxiong Huang Nature Medicine volume 32（9）, pages 3268–3275 35 Decade-long persistence of CD19 CAR T cells in B cell lymphomas CD19 CAR-T细胞在B细胞淋巴瘤体内可长达十年持续存在 Luca Paruzzo, Emeline R. Chong, Marco Ruella Nature Medicine volume 32（9）, pages 3276–3287 36 First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial PD-1/VEGF双特异性抗体联合化疗一线治疗三阴性乳腺癌：Ⅱ期临床试验 Xiying Shao, Can Tian, Quchang Ouyang Nature Medicine volume 32（9）, pages 3288–3293 Collection: Cancer at Nature Portfolio 合集：Nature系列肿瘤专题 37 KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial KRAS-G12D抑制剂HRS-4642联合化疗治疗晚期KRASG12D突变胰腺癌：Ⅰb/Ⅱ期临床试验 Jiujie Cui, Kuirong Jiang, Liwei Wang Nature Medicine volume 32（9）, pages 3294–3301 38 Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial 口服KRAS G12D抑制剂GFH375用于经治晚期KRAS G12D突变实体瘤：Ⅰ期临床试验 Xinghao Ai, Zhengbo Song, Shun Lu Nature Medicine volume 32（9）, pages 3302–3312 39 Global breast cancer survival estimates in 2017–2021 to advance the WHO Global Breast Cancer Initiative 2017–2021全球乳腺癌生存率估算，助力WHO全球乳腺癌防治计划 Fabio Girardi, Mary Nyangasi, André M. Ilbawi Nature Medicine volume 32（9）, pages 3313–3321 40 Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Mitiperstat抑制髓过氧化物酶治疗射血分数保留或轻度降低心力衰竭：一项随机Ⅱb期试验 Lars H. Lund, Carolyn S. P. Lam, Sanjiv J. Shah Nature Medicine volume 32（9）, pages 3322–3330 41 Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial 心肌内注射同种异体人诱导多能干细胞来源心肌细胞治疗晚期缺血性心力衰竭：一项早期随机试验 He Zhang, Phlippe Menasche, Dongjin Wang Nature Medicine volume 32（9）, pages 3331–3338 42 Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial 靶向RAGE的吸入型siRNA治疗肺部炎症：首次人体随机试验 Mark O’Carroll, David Kasahara, Nadwipa Yuangtrakul Nature Medicine volume 32（9）, pages 3339–3350 43 Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction Isthmin-2可在孕早期预测子痫前期与胎儿生长受限 Ruoyu Miao, Sungsam Gong, Anna Sandström Nature Medicine volume 32（9）, pages 3351–3358 44 Citywide implementation of a rapid whole-genome sequencing program for critically ill pediatric patients 面向危重患儿的全市快速全基因组测序项目落地实施 Fatma Rabea, Ibtesam Aljasmi, Ahmad Abou Tayoun Nature Medicine volume 32（9）, pages 3359–3371 45 A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial CD3×CD19双特异性抗体治疗系统性红斑狼疮：Ⅰ期临床试验 Jason Xu, Chunli Mei, Qiubai Li Nature Medicine volume 32（9）, pages 3372–3384 46 Antifungal therapy improves microbiome dynamics in inflammatory bowel disease 抗真菌治疗可改善炎症性肠病的微生物组动态特征 Xiangyu Pan, Aidan Conroy, Iliyan D. Iliev Nature Medicine volume 32（9）, pages 3385–3395 47 Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial 屈大麻酚治疗创伤后应激障碍相关噩梦：一项随机对照试验 Stefan Roepke, Nikola Schoofs, Stefanie Koglin Nature Medicine volume 32（9）, pages 3396–3405 48 Global economic burden of depression in 154 countries from 2025 to 2050 2025–2050年154个国家抑郁症的全球经济负担 Zhong Cao, Yuheng Luo, Simiao Chen Nature Medicine volume 32（9）, pages 3406–3416 49 Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS 纵向血浆蛋白质组学可预测肌萎缩侧索硬化表型转化至临床发病 Ximing Ran, Joanne Wuu, Michael Benatar Nature Medicine volume 32（9）, pages 3417–3429 50 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial 公立医疗体系中裸盖菇素辅助治疗难治性重度抑郁症：随机对照试验 James J. Rucker, Tim Mantingh, Allan H. Young Nature Medicine volume 32（9）, pages 3430–3437 51 An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up iPSC来源神经前体细胞治疗亚急性脊髓损伤：带长期随访的Ⅰ期临床试验 Keiko Sugai, Osahiko Tsuji, Hideyuki Okano Nature Medicine volume 32（9）, pages 3438–3448 52 Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial 人胚胎干细胞来源多巴胺能细胞治疗帕金森病：Ⅰ/Ⅱ期开放标签试验 G. Paul, H. Bjartmarz, R. A. Barker Nature Medicine volume 32（9）, pages 3449–3457 53 Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial 短效抗PD-L1抗体免疫治疗阿尔茨海默病：Ⅰb期随机双盲试验 Tommaso Croese, Catherine J. Mummery, Michal Schwartz Nature Medicine volume 32（9）, pages 3458–3465 54 Histological aging signatures for monitoring tissue-specific aging and disease 用于监测组织特异性衰老与疾病的组织学衰老特征 Ernesto Abila, Iva Buljan, André F. Rendeiro Nature Medicine volume 32（9）, pages 3466–3476 Analysis（分析） 55 Responsiveness of epigenetic aging biomarkers to longevity interventions in humans 人类表观遗传衰老生物标志物对长寿干预措施的应答性 Raghav Sehgal, Daniel Borrus, Albert Higgins-Chen Nature Medicine volume 32（9）, pages 3477–3490 Amendments & Corrections（修订与勘误） 56 Author Correction: Evolution of claudin18.2 therapies in gastroesophageal cancers 作者勘误：Claudin18.2靶向疗法在胃食管肿瘤中的研究进展 Samuel J. Klempner, Raghav Sundar Nature Medicine volume 32（9）, page 3491 57 Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms 作者勘误：组织细胞肿瘤中CSF1R及其他受体酪氨酸激酶的激活突变 Benjamin H. Durham, Estibaliz Lopez Rodrigo, Omar Abdel-Wahab Nature Medicine volume 32（9）, pages 3491–3492 58 Author Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 作者勘误：多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie Gomez, Rachel A. DiCioccio, Eugene I. Hwang Nature Medicine volume 32（9）, page 3493 59 Author Correction: The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence 作者勘误：人工智能诊断准确性研究报告规范STARD-AI Viknesh Sounderajah, Ahmad Guni, Trishan Panch Nature Medicine volume 32（9）, page 3493 60 Author Correction: Integrated community-based HIV and sexual and reproductive health services for youth: a cluster-randomized trial 作者勘误：面向青少年的社区HIV与性生殖健康整合服务：整群随机试验 Rashida A. Ferrand, Ethel Dauya, Richard J. Hayes Nature Medicine volume 32（9）, page 3494 61 Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas 出版方勘误：CD19 CAR-T细胞在B细胞淋巴瘤体内可长达十年持续存在 Luca Paruzzo, Emeline R. Chong, Marco Ruella Nature Medicine volume 32（9）, page 3495 62 Editorial Expression of Concern: Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury 编辑部关切声明：遗传谱系示踪研究提示干细胞可修复损伤后成年哺乳动物心肌细胞 Patrick C. H. Hsieh, Vincent F. M. Segers, Richard T. Lee Nature Medicine volume 32（9）, page 3496 63 Editorial Expression of Concern: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis 编辑部关切声明：CDK4与Ras共表达可诱发人表皮恶性肿瘤 Mirella Lazarov, Yoshiaki Kubo, Paul A. Khavari Nature Medicine volume 32（9）, page 3497 Nature Medicine Volume 32 Issue 10 自然医学 32卷 10期 https://www.nature.com/nm/volumes/32/issues/10 Editorial（社论） 1 Making AI work in healthcare 让人工智能在医疗领域落地应用 Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, page 3499 News（新闻） 2 Induced proximity comes of age 诱导邻近技术走向成熟 Natalie Healey Nature Medicine volume 32（10）, pages 3500–3502 Correspondence（通信） 3 Beyond Ebola: armed conflict and humanitarian funding cuts threaten control of malaria, TB and HIV in eastern DRC 埃博拉之外：武装冲突与人道主义资金削减威胁刚果民主共和国东部疟疾、结核病与艾滋病防控 Roland Muhindo MuyisaVivuya Kavugho LoandoJean Paul Paluku Mwalitsa Nature Medicine volume 32（10）, pages3503–3504 4 A binding ban, and its limits: Japan legislates on heritable human genome editing 具有约束力的禁令及其局限：日本制定可遗传人类基因组编辑相关法律 Tsutomu Sawai Nature Medicine volume 32（10）, pages 3505–3506 5 The Value Cube: translating clinical benefit into realizable value in global oncology 价值立方体：在全球肿瘤学中将临床获益转化为可实现价值 Bibek AryalOphira GinsburgDario Trapani Nature Medicine volume 32（10）, pages 3507–3508 6 Overcrowded Ebola treatment centers are fueling transmission in the Democratic Republic of the Congo 刚果民主共和国埃博拉治疗中心人满为患加剧病毒传播 Justin Kambale KahingiLionel Shotsha AsamboaRoland Muhindo Muyisa Nature Medicine volume 32（10）, pages 3509–3510 World View（全球视角） 7 Sex and gender differences belong in treatment guidelines 治疗指南应当纳入性别相关差异 Alexandra Kautzky-Willer Nature Medicine volume 32（10）, pages 3511 Comment（述评） 8 Lessons from deploying the ChatEHR system at Stanford Medicine 斯坦福医学院部署ChatEHR系统的经验 Nigam H. ShahNiraj SehgalMichael A. Pfeffer Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3512–3515 9 Prospective evidence for conversational medical AI is hard, but non-negotiable 对话式医疗人工智能的前瞻性证据获取虽难，但不可或缺 Mike SchaekermannAnil PalepuPo-Hsuan Cameron Chen Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3516–3519 10 Initial lessons from real-world implementation of an AI-agent eye clinic in China 国内人工智能智能代理眼科门诊真实世界落地的初步经验 Tao YanDi ZhangTien Yin Wong Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3520–3524 11 Practical lessons in the global scaling of clinical AI: from one hospital to over a million patients screened 临床人工智能全球推广的实践经验：从单家医院到超百万例筛查患者 Richa TiwariRajroshan SawhneySunny Virmani Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3525–3527 12 Frugal AI is the missing piece in cervical cancer screening 低成本简易人工智能是宫颈癌筛查中缺失的一环 Johnblack K. KabukyeJaap A. R. KootCaroline Wamala-Larsson Collections: Cancer at Nature Portfolio Nature Medicine series on real-world clinical AI deployment 合集：《自然》出版集团癌症专题合集；《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3528–3530 13 From algorithms to patient outcomes — lessons from one of the first randomized trials of AI in medicine 从算法到患者结局——首批医学人工智能随机试验带来的启示 Kristina Lång Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3531–3533 14 A global digital navigator of human health for precision medicine 面向精准医学的全球人类健康数字导航平台 Kang ZhangJiahong DongGuang Ning Nature Medicine volume 32（10）, pages 3534–3538 News & Views（新闻与观点） 15 The missing links in agentic AI autonomy 智能代理自主性研究中缺失的关键环节 Mahmud OmarRaja-Elie E. AbdulnourGirish N. Nadkarni Nature Medicine volume 32（10）, pages 3539–3540 16 Some answers, more questions for multi-cancer early detection tests 多癌种早期检测试验：得到部分答案，更多问题尚存 Catherine R. MarinacTimothy R. RebbeckElizabeth K. O’Donnell Nature Medicine volume 32（10）, pages 3541–3542 17 Our Future Health and the next generation of population medicine “我们的未来健康”项目与下一代群体医学 Zhonghan SunYan Zheng Nature Medicine volume 32（10）, pages 3543–3544 Research Briefings（研究简报） 18 Altered oligodendrocyte function promotes cognitive decline in aging 少突胶质细胞功能异常促进衰老相关认知衰退 Nature Medicine volume 32（10）, pages 3545–3546 19 De novo mutations bridge parental reproductive factors and offspring health 新发突变搭建亲代生殖因素与子代健康之间的关联 Nature Medicine volume 32（10）, pages 3547–3548 20 Gene alteration in human brain suggests genetic and epigenetic roots of major depression 人脑基因改变提示重度抑郁症存在遗传与表观遗传学根源 Nature Medicine volume 32（10）, pages 3549–3550 Perspectives（观点） 21 Redesigning cardiovascular medicine around sex differences 围绕性别差异重构心血管疾病诊疗体系 Elisa Dal CantoErnest Diez BenaventeHester den Ruijter Nature Medicine volume 32（10）, pages 3551–3563 Review Articles（综述） 22 Reproducibility in biomedical research 生物医学研究的可重复性 Judy ZhongDebra D’AngeloRainu Kaushal Nature Medicine volume 32（10）, pages 3564–3577 Consensus Statements（共识声明） 23 A consensus-based guideline for personalized bacteriophage therapy 基于共识的个体化噬菌体治疗指南 Silvia WürstleSimone C. Lieberknecht-JouySandra Zumpfe Nature Medicine volume 32（10）, pages 3578–3594 Matters Arising（争议讨论） 24 Limited benchmarks constrain the conclusions of a general-purpose versus clinical AI comparison 基准测试数据不足限制通用人工智能与临床人工智能对比研究结论的可靠性 Brett Beaulieu-JonesShamim Nemati Nature Medicine volume 32（10）, pages 3595–3597 25 Reply to: Limited benchmarks constrain the conclusions of a general-purpose versus clinical AI comparison 答复《基准测试数据不足限制通用人工智能与临床人工智能对比研究结论的可靠性》 Krithik VishwanathYindalon AphinyanaphongsEric Karl Oermann Nature Medicine volume 32（10）, pages 3598–3599 Brief Communications（短讯） 26 A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir 采用单克隆抗体联合瑞德西韦治疗本迪布焦病毒病病例1例 Alexander UhrigFrieder PfäfflinThomas Zoller Nature Medicine volume 32（10）, pages 3600–3605 27 Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children 成人与儿童接触本迪布焦埃博拉病毒后采用单克隆抗体鸡尾酒方案进行暴露后预防 Christian GaeblerHan Ngoc LeThomas Zoller Nature Medicine volume 32（10）, pages 3606–3611 28 Recombinant shingles vaccination and the risk of cardiovascular events 重组带状疱疹疫苗接种与心血管事件风险 Fabiana Corsi-ZuelliFang LiMaxime Taquet Nature Medicine volume 32（10）, pages 3612–3616 Articles（论著） 29 Emergence of a Bundibugyo virus variant in the 2026 outbreak in the Democratic Republic of the Congo and Uganda 2026年刚果民主共和国与乌干达疫情中本迪布焦病毒变异株的出现 Adrienne Amuri-AzizaGradi Luakanda-NdelemoPardis Sabeti Nature Medicine volume 32（10）, pages 3617–3621 30 Small quantity lipid-based nutritional supplementation and measles vaccination coverage in children aged 6−23months: a pragmatic cluster-randomized trial 少量脂基营养补充剂与6~23月龄儿童麻疹疫苗接种率：一项实用性整群随机试验 Cécile CazesBaba Waru GoniKevin P. Q. Phelan Nature Medicine volume 32（10）, pages 3622–3632 31 COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer 全国癌症患者队列：免疫检查点抑制剂启用前后接种新冠疫苗与患者生存的关联 Joe-Elie SalemRaphaelle CurminFlorence Tubach Nature Medicine volume 32（10）, pages 3633–3643 32 Traumatic brain injury outcomes across human development index strata in 29 countries 29个国家不同人类发展指数分层下创伤性脑损伤的疾病结局 Joseph G. NugentHao TanSalwa Al Aryani Nature Medicine volume 32（10）, pages 3644–3660 33 Oligodendrocyte dysfunction in human age-related cognitive decline 人类衰老相关认知衰退中的少突胶质细胞功能障碍 Georgina A. CraigEmeric MerourVéronique E. Miron Nature Medicine volume 32（10）, pages 3661–3671 34 Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial 奥妥珠单抗β治疗水通道蛋白4阳性视神经脊髓炎谱系疾病：一项Ⅲ期随机对照试验 Lei WuLiangliang GuBin Li Nature Medicine volume 32（10）, pages 3672–3681 35 AI-based characterization of Alzheimer’s disease phenotypes from population-scale single-cell data 基于人工智能利用人群规模单细胞数据解析阿尔茨海默病表型 Chenfeng HeAthan Z. LiZhiping Shao Collection: PsychAD Consortium 合集：PsychAD联盟专题 Nature Medicine volume 32（10）, pages 3682–3694 36 An open vision-language model for diverse medical applications 面向多样化医学应用的开源视觉语言模型 Andrew SellergrenSahar KazemzadehLin Yang Nature Medicine volume 32（10）, pages 3695–3704 37 On-premise medical AI agents for reliable clinical decision-making 本地部署医疗智能代理用于可靠临床决策 Li ZhangGeorg WölfleinJakob Nikolas Kather Nature Medicine volume 32（10）, pages 3705–3716 38 Large-scale AI-guided liver malignancy diagnosis: multicenter study and a single-arm trial 人工智能辅助大规模肝脏恶性肿瘤诊断：多中心研究与单臂临床试验 Xiaoming ZhangChunli LiYu Shi Nature Medicine volume 32（10）, pages 3717–3729 39 A clinically validated framework for auditing AI chatbot behavior in mental health interactions 经临床验证的心理健康对话场景下AI聊天机器人行为审计框架 Veith WeilnhammerKevin YC HouMatthew M. Nour Collection: Nature Medicine series on real-world clinical AI deployment 合集：《自然·医学》真实世界临床人工智能部署系列 Nature Medicine volume 32（10）, pages 3730–3740 40 Prospective evaluation of a large language model clinical decision support system in the emergency department 急诊科大语言模型临床决策支持系统的前瞻性评价 Liron LeibovitchAdi AhituvShahar Shelly Nature Medicine volume 32（10）, pages 3741–3747 41 Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence 基于非增强CT与人工智能的大规模食管癌筛查 Jian ZhouGuangyu GuoQifeng Wang Collection: Cancer at Nature Portfolio 合集：《自然》出版集团癌症专题合集 Nature Medicine volume 32（10）, pages 3748–3759 42 Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study 多癌种早期检测试验的检测效能与安全性：PATHFINDER 2研究 Nima NabavizadehCharles McDonnellKarthik V. Giridhar Collection: Cancer at Nature Portfolio 合集：《自然》出版集团癌症专题合集 Nature Medicine volume 32（10）, pages 3760–3769 43 Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial NHS-Galleri随机对照试验中多癌种早期检测试验的检测效能 Richard D. NealSaoirse DollyCharles Swanton Collection: Cancer at Nature Portfolio 合集：《自然》出版集团癌症专题合集 Nature Medicine volume 32（10）, pages 3770–3780 44 Liquid biopsy for early detection of pancreatic ductal adenocarcinoma 液体活检用于胰腺导管腺癌早期筛查 Caiming XuAlessandro MannucciAjay Goel Nature Medicine volume 32（10）, pages 3781–3791 45 Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma 左乙拉西坦可靶向作用于弥漫性中线胶质瘤的γ-氨基丁酸能突触发挥治疗作用 Tara BarronRichard DrexlerMichelle Monje Nature Medicine volume 32（10）, pages 3792–3800 46 Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial 阿替利珠单抗用于早期三阴性乳腺癌：Ⅲ期随机NSABP B-59/GeparDouze试验 Sibylle LoiblGong TangCharles E. Geyer Jr. Collection: Cancer at Nature Portfolio 合集：《自然》出版集团癌症专题合集 Nature Medicine volume 32（10）, pages 3801–3811 47 Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial 特立妥单抗对比来那度胺联合地塞米松治疗高危冒烟型多发性骨髓瘤：一项Ⅱ期随机试验 Omar NadeemDavid M. Cordas dos SantosIrene M. Ghobrial Collection: Cancer at Nature Portfolio 合集：《自然》出版集团癌症专题合集 Nature Medicine volume 32（10）, pages 3812–3822 48 Population-scale reconstruction of menopause dynamics reveals a physiological cliff at the final menstrual period 人群尺度重建绝经动态变化：末次月经存在生理断崖式改变 Glen PridhamYoav HayutUri Alon Nature Medicine volume 32（10）, pages 3823–3831 49 A multi-faceted hospital-based intervention for intrapartum care in sub-Saharan Africa: a stepped-wedge cluster-randomized trial 撒哈拉以南非洲产时保健的多维度院内干预：阶梯式整群随机试验 Claudia HansonJoseph AkuzeBeatrice Mwilike Nature Medicine volume 32（10）, pages 3832–3841 50 Large-scale whole-genome sequencing reveals the landscape and health implications of de novo mutations 大规模全基因组测序揭示新发突变图谱及其对健康的影响 Na QinJuncheng DaiZhibin Hu Nature Medicine volume 32（10）, pages 3842–3852 51 Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial Padua型凝血因子IX腺相关病毒基因治疗用于青少年B型血友病：Ⅰ期临床试验 Feng XueAi ZhangLei Zhang Nature Medicine volume 32（10）, pages 3853–3861 52 CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial CD19 CAR-T细胞治疗难治性血清阳性类风湿关节炎：Ⅰ期临床试验 Fredrik N. AlbachMarie C. RehmGerhard Krönke Nature Medicine volume 32（10）, pages 3862–3873 53 Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium 心力衰竭联合用药方案对血压、肾功能及血钾的短期影响 Nelson WangBrian L. ClaggettMuthiah Vaduganathan Nature Medicine volume 32（10）, pages 3874–3883 54 Dysregulated adult hippocampal neurogenesis in major depressive disorder 重度抑郁症中成人海马神经发生调控异常 Madeleine S. PengJialin JiangMaura B. Dupont Nature Medicine volume 32（10）, pages 3884–3898 Resources（资源） 55 Phenomic profiles and disease patterns of 1.9 million participants from Our Future Health “我们的未来健康”项目190万受试者的表型组特征与疾病模式 Vincent J. StraubStefania BenonisdottirMelinda C. Mills Nature Medicine volume 32（10）, pages 3899–3910 Amendments & Corrections（修订与勘误） 56 Author Correction: Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial 作者勘误：结肠镜联合粪便免疫化学检测对比常规诊疗用于结直肠癌诊断性筛查：SCREESCO随机对照试验 Marcus WesterbergJonas F. LudvigssonAnna Forsberg Nature Medicine volume 32（10）, page 3911 57 Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance 作者勘误：敲除脂肪脂解、产热与氧化代谢调控因子TRIP-Br2可预防饮食诱导的肥胖与胰岛素抵抗 Chong Wee LiewJeremie BoucherRohit N Kulkarni Nature Medicine volume 32（10）, page 3912 58 Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial 作者勘误：Survodutide用于合并代谢相关脂肪性肝病的肥胖成人患者：SYNCHRONIZE-MASLD随机、双盲、安慰剂对照Ⅲ期试验 Lee M. KaplanElena StartsevaPaul Hellstern Nature Medicine volume 32（10）, page 3913

临床1期细胞疗法免疫疗法

2026-10-19

·畅好约

2026 白癜风新药汇总！十几款管线分成四大赛道，哪一条最值得等？

白癜风新药研究迎来爆发，粗略梳理，今年有数据更新、进入临床阶段的候选药已经有十余款。靶点不再只扎堆传统 JAK 通路，TYK2、PDE4、IL‑15 等全新方向陆续交出早期结果，很多病友一边兴奋，一边分不清谁已经落地、谁还停留在试验阶段，更搞不懂它们之间核心差别在哪。今天我们把纷繁管线归为四大赛道，结合最新临床进展拆解清楚：它们分别瞄准什么问题、到了哪一步、适合什么样的白斑人群，同时划清一条很重要的边界 —— 热闹的前沿管线，不能替代当下成熟的规范治疗。一、赛道一：JAK 抑制剂，目前证据最扎实、离我们最近的主力方向 JAK 通路是现阶段整个白癜风领域验证最充分的靶点，又分为外用和口服两条分支。 1.外用阵营里，芦可替尼乳膏是标杆。 · 2026 年初国内正式获批上市，依托数千人规模的 TRuE-V 系列 III 期数据，已经进入常规临床选择。它的疗效特点是累积起效，坚持用到 24 周、52 周，面部复色达标率会持续走高，也是大家最熟悉的靶向外用药。 · LNK01004 软膏由北大人民医院牵头开展临床试验，属于软性外用剂型，按当前节奏预估申报节点落在 2028–2029 年。 · 恒瑞的 SHR0302 凝胶同样是本土管线，即将迈入 II 期探索阶段，距离上市还有数年等待周期。 2.口服 JAK 则面向范围更广、处在快速进展期的泛发性白斑患者，多款重磅候选陆续读出 III 期结果： · 乌帕替尼属于高选择性 JAK1 抑制剂，全球 III 期试验顺利完成，海外计划 2026 下半年拿到白癜风适应症； · 泊沃昔替尼（Povorcitinib）两项关键全球 III 期全部达到终点，国内由康哲药业引进，有望在 2027 年率先在国内递交申请； · 利特昔替尼（Ritlecitinib）走 JAK3/TEC 通路，正在推进 III 期，它对 IL‑2、IL‑15 信号都有干预，研发上更看重反复复发人群；除此之外，巴瑞替尼、托法替布、多款国产 TYK2 选择性抑制剂，也在各自的 II、III 期阶段持续积累数据。二、赛道二：PDE4 外用制剂，外用家族里的新备选在 JAK 之外，外用赛道里 PDE4 抑制剂是关注度很高的一支，代表管线来自 Arcutis Biotherapeutics。这家企业的罗氟司特（ZORYVE）乳膏已经获批用于银屑病、脂溢性皮炎，安全性和外用耐受特征已有临床积累。现在企业正在拓展白癜风适应症，计划在 2026 年第四季度，基于 II 期临床试验的结果，决定后续研发是否继续向前推进。三、赛道三：选择性 TYK2 口服小分子，主打更安全的长期维稳 TYK2 属于 JAK 家族分支，但和传统泛 JAK、JAK1 抑制剂设计思路完全不同。它追求靶点高度专一，尽量避开其他 JAK 亚型，目的就是降低大家最担心的感染、血脂波动等全身性风险，定位偏向长期控制、稳定免疫环境，减少复发。代表药物是 Soficitinib（ICP‑332），国产管线，II 期临床顺利达标，已经进入 II/III 期衔接阶段。从现有早期数据看，它的安全性信号优于很多广谱 JAK，预估 2028 年有望申报上市。同赛道还有多款 TYK2 候选同步在 II 期验证疗效，核心逻辑都是 “精准控免疫，减少长期用药顾虑”。四、赛道四：IL‑15 精准生物制剂，今年最出圈的 “抗复发” 方向这是很多前沿研究者眼中最有想象力的赛道，也是专门针对白癜风复发痛点设计的。大家反复复发的根源，在于皮肤里扎根的组织驻留记忆 T 细胞（TRM），这类细胞依靠 IL‑15 维持存活；就算白斑复色，只要它们还潜伏在皮损内，停药之后很容易再次发起攻击、破坏黑素细胞。而 IL‑15 单抗，就是直接阻断这条供养通路，慢慢清除这批致病记忆细胞，追求停药后依然稳住色素。 2026 年至少 6 款同类单抗进入不同阶段临床：安进 Ordesekimab、AMG714，梯瓦 TEV‑408 长效抗体，诺华 GIA632；国内也有智翔金泰 GR2301、信达 IBI3013 长效款、迈威 9MW5211、EV‑53408 等管线。目前这批产品大多处于 II 期招募和数据读出阶段，距离正式上市还有漫长的验证周期。理性提醒：不要盲目追新药上面四大赛道里，绝大多数候选药物还没有走完完整 III 期确证流程。这意味着，长期使用的安全数据、数年尺度下的真实复发率、不同人种的应答差异，都还缺少足够大样本支撑。一款新药从 II 期阳性到最终获批，中途调整、终止研发的情况在行业里并不少见。我们不必因为一堆新药消息，否定已经成熟的方案，在维持现有治疗方案基础上，再持续跟踪管线动态，才是稳妥思路。#白癜风 #畅好约 #公益援助本文内容仅为前沿科研资讯科普，不构成诊疗推荐；所有白癜风用药方案，请遵从正规医院皮肤科医生面诊评估。参考文献 [1]诺诚健华. Soficitinib（ICP-332）治疗非节段型白癜风 II 期研究达到主要终点，2026 [2]AbbVie. Upadacitinib for non-segmental vitiligo Phase 3 topline results, 2026

临床3期临床2期上市批准申请上市

2026-10-19

·白癜风手拉手

泊沃昔替尼三期数据出炉！又一款口服JAK新药，给中重度白癜风添新选择

很多白斑朋友长期依靠外用药、光疗对抗白斑，漫长的治疗周期，加上大面积皮损、面部白斑难以坚持频繁照光的困扰，让不少中重度患者一直在寻找更便捷的全身治疗方案。白癜风新药研发持续提速，Incyte 公司的高选择性 JAK1 抑制剂泊沃昔替尼公布两项关键三期临床试验阳性结果，所有预设终点全部达标，为中重度非节段型白癜风带来全新的口服治疗候选方案。泊沃昔替尼的作用原理，阻断白斑持续扩散的免疫链条白癜风本质是体内 CD8 阳性 T 细胞异常活化，持续释放炎症因子，不断招募免疫细胞攻击皮肤里的黑素细胞。免疫攻击不停，白斑就容易持续扩散，就算复色之后也存在复发风险。泊沃昔替尼作为高选择性 JAK1 口服抑制剂，并不会直接催生皮肤色素，核心作用是精准阻断 JAK‑STAT 炎症信号通路，减轻干扰素介导的皮肤免疫炎症，切断免疫细胞持续损伤黑素细胞的过程。对比早期广谱 JAK 抑制剂，这款药物只靶向 JAK1，对体内其他 JAK 通路干扰更小，在控制白斑、促进复色的同时，尽可能降低额外通路干扰带来的潜在风险。当前 JAK 通路是白癜风新药研发最热门的方向，外用制剂与多款口服药物陆续公布临床数据，每一款药物的靶点特性、适用范围和安全特点各不相同，泊沃昔替尼主要面向需要口服方案、追求靶点高选择性的中重度白斑人群。三期临床数据解读，一年长期治疗的疗效与安全性本次公布的 STOP‑V1、STOP‑V2 两项全球三期试验，一共纳入 900 多名成年中重度非节段型白癜风受试者，采用严谨的随机双盲安慰剂对照设计，受试者每日口服 30mg 泊沃昔替尼，持续治疗 52 周，用来评估长期疗效和安全表现。临床评价主要参考两个核心指标，面部白斑改善 75% 的 F-VASI75，以及全身白斑改善达到 50% 的 T-VASI50。为期一年的随访结果显示，服药一年后，药物组达到面部白斑改善 75% 标准的受试者占 18.9%，安慰剂对照组达标率仅为 6.8%、3.1%，差异显著，全身白斑改善的次要终点同样取得阳性结果，全身皮损的复色效果得到验证。在安全性观察周期内，没有发现全新的不良反应，用药产生的轻微不适和二期研究结果保持一致，整体耐受性稳定。更早的剂量探索研究也能看出，药物的复色效果会随治疗时间逐步显现，并非短期临时改善，长期坚持用药色素恢复潜力会慢慢释放。哪些白斑患者可以重点关注这款候选新药这款口服新药并不是适合所有白癜风人群，结合临床试验的入组要求，更有可能从中获益的，是全身多处泛发白斑的非节段型患者，白斑处于进展期、皮损持续扩散的人群，还有面部白斑明显，对生活和心理影响较大，皮损范围广，难以长期坚持反复光疗、大面积涂抹外用制剂的患者。对于小面积、稳定的局限型白斑，现有的外用药联合光疗方案已经有不错的复色效果，不需要盲目等待这款口服新药。理性看待新药，切勿通过非正规渠道尝试泊沃昔替尼目前还未获得上市批准，按照研发企业计划，预计下半年率先在欧洲提交白癜风适应症上市申请，美国申报安排在 2027 年一季度，国内暂无上市时间表。现阶段网络上各类代购、私人渠道的货源都不属于正规药品，私自购买服用属于违规试药。白癜风的治疗方案越来越丰富，新药研发不断突破，但新药的价值，是为传统方案效果不佳、治疗负担沉重的中重度泛发患者增加一项治疗选择。口服免疫相关药物存在潜在安全风险，必须在专业医生完善基线筛查、全程监测随访的前提下评估使用，千万不要跟风自行购药，避免带来感染、血脂异常等各类健康隐患。

临床2期临床3期临床结果

100 项与磷酸泊沃昔替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12575 D12576	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自身免疫性疾病	申请上市	加拿大	Incyte Corp.	2026-07-01
化脓性汗腺炎	申请上市	美国	Incyte Corp.	-
化脓性汗腺炎	申请上市	欧盟	Incyte Corp.	-
结节性痒疹	临床3期	美国	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	日本	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	阿根廷	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	澳大利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	奥地利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	比利时	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	保加利亚	Incyte Corp.	2024-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04818346 (Pubmed \| Adv Ther)	临床2期	白癜风	103	Povorcitinib 15 mg	簾簾廠鹽獵簾夢築築積(壓製壓鏇淵餘齋壓觸顧) = 艱襯顧糧獵醖構艱夢衊範艱淵齋構糧簾鹹窪築 (鹹顧獵醖網廠糧繭衊繭 ) 更多	积极	2026-10-01
NCT04818346 (Pubmed \| Dermatol Ther (Heidelb))	临床2期	-	162	Povorcitinib	蓋襯觸網範鹹憲製積淵(廠淵選築築齋獵壓憲鹽) = 齋餘廠衊鬱齋膚膚餘簾鹽壓積鑰願膚糧齋願糧 (範簾憲鹽襯淵鹽齋構鑰 ) 更多	积极	2026-08-01
NCT05936567 (AAD2026)	临床2期	慢性荨麻疹	136	Povorcitinib 15mg	鏇觸簾構醖鏇鬱簾積鹹(範鏇鹹鏇衊獵膚簾製壓) = 醖製蓋網鬱夢醖繭衊鏇繭窪糧築淵鏇廠壓夢鹽 (範膚觸範膚繭蓋膚製構, 2.94)	积极	2026-03-27
				Povorcitinib 45mg	鏇觸簾構醖鏇鬱簾積鹹(範鏇鹹鏇衊獵膚簾製壓) = 遞窪鑰齋衊構廠鏇鹽願繭窪糧築淵鏇廠壓夢鹽 (範膚觸範膚繭蓋膚製構, 2.78)
AAD2026	N/A	化脓性汗腺炎	177	povorcitinib	壓鑰鏇齋襯獵齋願鹹遞(獵鏇獵範廠憲鏇鹽繭鏇) = 壓鹹製製觸糧襯繭齋願觸齋鬱壓襯鹹鏇艱範艱 (夢築鏇艱鏇鹹鹽觸窪壓 )	积极	2026-03-27
				Placebo	壓鑰鏇齋襯獵齋願鹹遞(獵鏇獵範廠憲鏇鹽繭鏇) = 膚製製艱願糧鑰壓願範觸齋鬱壓襯鹹鏇艱範艱 (夢築鏇艱鏇鹹鹽觸窪壓 )
NCT05936567 (CTgov)	临床2期	瘙痒 \| 慢性荨麻疹 \| 血管性水肿	136	placebo (Placebo)	鹽獵憲窪範網壓鹽窪願(簾餘選廠齋網獵醖糧願) = 廠鹹願鬱遞齋製網製簾夢衊淵蓋膚鏇鬱衊膚構 (鹽襯淵製壓淵膚鹽窪鹹, 2.21) 更多	-	2026-03-12
				Povorcitinib (Povorcitinib 15 mg QD)	鹽獵憲窪範網壓鹽窪願(簾餘選廠齋網獵醖糧願) = 築夢鹹鹽願鑰獵製艱構夢衊淵蓋膚鏇鬱衊膚構 (鹽襯淵製壓淵膚鹽窪鹹, 2.09) 更多
NCT06505265 (Pubmed \| Bioanalysis)	临床1期	-	18	Povorcitinib	遞衊憲鹽選醖築鏇願願(淵構觸選範製壓簾選憲) = 網窪淵積壓繭醖醖構壓遞窪獵築窪獵壓鏇憲醖 (齋壓獵獵憲遞淵獵製簾 )	积极	2026-01-08
NCT04818346 (Pubmed \| J Am Acad Dermatol)	临床2期	白癜风	171	Povorcitinib 15 mg	繭顧艱淵鹹廠範網廠繭(顧製淵選襯選憲廠築獵) = 製衊鑰簾製構範壓製衊窪獵簾獵蓋鑰鏇網顧憲 (鹽鏇憲鹽廠憲壓觸獵鹹 )	积极	2025-10-01
				Povorcitinib 45 mg	繭顧艱淵鹹廠範網廠繭(顧製淵選襯選憲廠築獵) = 選遞醖襯窪齋顧範構襯窪獵簾獵蓋鑰鏇網顧憲 (鹽鏇憲鹽廠憲壓觸獵鹹 )
NCT05620836 \| NCT05620823 (STOP-HS2, Company_Website) 人工标引	临床3期	化脓性汗腺炎	-	Povorcitinib 45 mg (STOP-HS1)	選襯餘廠積鏇餘鑰襯艱(鏇顧淵鬱夢膚觸鹹鬱餘) = 觸遞鬱餘簾餘網鏇襯鑰齋鏇壓製遞齋襯遞齋襯 (廠願積糧範夢簾憲壓糧 ) 达到更多	积极	2025-03-17
				Povorcitinib 75 mg (STOP-HS1)	選襯餘廠積鏇餘鑰襯艱(鏇顧淵鬱夢膚觸鹹鬱餘) = 糧鑰遞觸構餘製願醖鑰齋鏇壓製遞齋襯遞齋襯 (廠願積糧範夢簾憲壓糧 ) 达到更多
NCT04818346 (AAD2024) 人工标引	临床2期	白癜风	171	Povorcitinib (age≤40 years)	顧鏇簾鏇積築獵獵鹹蓋(遞壓夢艱憲顧築鹽製顧) = 獵範襯膚廠襯網膚膚簾網廠衊構餘觸鑰廠廠衊 (願簾夢膚襯淵憲範遞選 )	积极	2024-03-10
				Povorcitinib (age>40 years)	顧鏇簾鏇積築獵獵鹹蓋(遞壓夢艱憲顧築鹽製顧) = 顧膚範觸鹹觸窪襯鑰遞網廠衊構餘觸鑰廠廠衊 (願簾夢膚襯淵憲範遞選 )
NCT05061693 (Corporate Publications) 人工标引	临床2期	结节性痒疹	146	Povorcitinib 15 mg	齋繭繭鹽壓醖願鏇遞膚(觸鑰廠鏇鏇鑰衊製衊淵) = 鏇艱鏇鹽遞築範鏇構簾醖觸衊艱觸選廠顧獵蓋 (顧窪糧襯選獵鑰願鹽鹽 ) 达到更多	积极	2024-03-10
				Povorcitinib 45 mg	齋繭繭鹽壓醖願鏇遞膚(觸鑰廠鏇鏇鑰衊製衊淵) = 鏇夢艱鑰齋鑰窪餘繭遞醖觸衊艱觸選廠顧獵蓋 (顧窪糧襯選獵鑰願鹽鹽 ) 达到更多